Anemia Clinical Trials

• Male or female participants of any race aged at least 18 years at time of initiation of luspatercept treatment

• Participants with documented diagnosis of transfusion-dependent β-thalassemia (TDT).

• Participants who have been initiated on treatment with luspatercept as per the product's Summary of Product Characteristics (SmPC) no longer than 12 months prior to informed consent signature, and for whom therapy is ongoing.

• Participants for whom the decision to prescribe luspatercept treatment is clearly separated from the physician's decision to include the participant in the current study.

• Participants who have provided signed informed consent for participating in the study and for collecting and analyzing medical data pertinent to the objectives of this study